Abstract
In this pilot study, 22 women with breast cancer on tamoxifen therapy with at least two hot flashes a day took oral gabapentin at 300 mg three times a day for 4 weeks. The 16 women who completed the study had a mean decrease in hot flash duration of 73.6% (P = 0.027), frequency of 44.2% (P < 0.001), and severity of 52.6% (P < 0.001), with a complete response in 8/16 women. Side effects reported by four women who did not complete 4 weeks of the study were nausea (1/4), rash (1/4) and excessive sleepiness (3/4). Two additional patients did not provide complete data. Gabapentin is a promising new agent in the treatment of tamoxifen induced hot flashes, and should be studied further.
References
Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Eng J Med 320: 479–484, 1989
Guttuso Jr TJ: Gabapentin's effects on hot flashes and hypothermia. Neurology 54(11): 2161–2163, 2000
Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windshitl H: Methodologic lessons learned from hot flash studies. J Clin Oncol 19: 4280–4290, 2001
Guttuso Jr TJ, Kurlan R, McDermott MP, Kieburtz K: Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 101: 337–345, 2003
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pandya, K.J., Thummala, A.R., Griggs, J.J. et al. Pilot Study using Gabapentin for Tamoxifen-induced Hot Flashes in Women with Breast Cancer. Breast Cancer Res Treat 83, 87–89 (2004). https://doi.org/10.1023/B:BREA.0000010676.54597.22
Issue Date:
DOI: https://doi.org/10.1023/B:BREA.0000010676.54597.22